Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MagSnow2: Ultra-low dose Magtrace for SLN detection in breast cancer
NCT06169072Phase 2Recruiting
- Sponsor
- Region Västra Götaland
- Start
- Jan 2023
- Primary completion
- Jul 2024
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of Magtrace in breast cancer, sponsored by Region Västra Götaland. Started Jan 2023; status: recruiting.
02
Drugs
Magtrace
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06169072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06169072.